Mauro Marigo

Title: Mauro Marigo: Inventor in Retinal Disease Research

Introduction

Mauro Marigo is an inventor based in Zurich, Switzerland, whose patent work focuses on potential treatments for retinal and neuroretinal diseases. He is associated with Endogena Therapeutics, Inc. His portfolio includes 4 patents.

Latest Patents

Two of Marigo’s latest patent disclosures concern compounds intended to address retinal disease and degeneration.

“Compounds and Their Use as Therapeutically Active Substances in the Treatment and/or Prevention of Diseases Involving the Retinal Pigment Epithelium” describes compounds and methods for treating or preventing diseases involving the retinal pigment epithelium. The disclosed method involves administering a specified compound or an acceptable salt or stereochemical form.

“N-(4-(Oxazol-5-yl)phenyl) Chromane-3-carboxamide Derivatives and Related Compounds as Stimulators of the Production of Retinal Precursor Cells for the Treatment of Neuroretinal Diseases” describes compounds and a method for treating retinal diseases associated with photoreceptor loss or outer-retina degeneration. The disclosure focuses on stimulating the production of retinal precursor cells through administration of specified compounds or their acceptable forms.

Career Highlights

Marigo’s patent activity reflects a focus on therapeutic approaches to retinal pigment epithelium disorders and neuroretinal degeneration. The inventions describe chemical compounds and methods of administration aimed at addressing these conditions.

Collaborations

Marigo is associated with Endogena Therapeutics, Inc. His listed coworkers include Matthias Steger and Alex Mueller.

Conclusion

Mauro Marigo’s patent portfolio highlights research into compound-based approaches for retinal and neuroretinal diseases, including conditions involving the retinal pigment epithelium and photoreceptor loss.